Format

Send to

Choose Destination
J Med Chem. 2019 May 9;62(9):4638-4655. doi: 10.1021/acs.jmedchem.9b00241. Epub 2019 Apr 29.

Novel Tetrahydroquinazolinamines as Selective Histamine 3 Receptor Antagonists for the Treatment of Obesity.

Author information

1
Academy of Scientific and Innovative Research (AcSIR) , New Delhi 110001 , India.
2
National Institute of Pharmaceutical Education and Research Raebareli , New Transit Campus, Bijnor Road , Sarojani Nagar, Near CRPF Base Camp, Lucknow , 226002 Uttar Pradesh , India.

Abstract

The histamine 3 receptor (H3R) is a presynaptic receptor, which modulates several neurotransmitters including histamine and various essential physiological processes, such as feeding, arousal, cognition, and pain. The H3R is considered as a drug target for the treatment of several central nervous system disorders. We have synthesized and identified a novel series of 4-aryl-6-methyl-5,6,7,8-tetrahydroquinazolinamines that act as selective H3R antagonists. Among all the synthesized compounds, in vitro and docking studies suggested that the 4-methoxy-phenyl-substituted tetrahydroquinazolinamine compound 4c has potent and selective H3R antagonist activity (IC50 < 0.04 μM). Compound 4c did not exhibit any activity on the hERG ion channel and pan-assay interference compounds liability. Pharmacokinetic studies showed that 4c crosses the blood brain barrier, and in vivo studies demonstrated that 4c induces anorexia and weight loss in obese, but not in lean mice. These data reveal the therapeutic potential of 4c as an anti-obesity candidate drug via antagonizing the H3R.

Supplemental Content

Full text links

Icon for American Chemical Society
Loading ...
Support Center